{"title":"血液透析患者的碳酸氢盐水平从碳酸镧转变为氢氧化铁。","authors":"Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas","doi":"10.5527/wjn.v7.i6.123","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To examine possible alterations in acid-base parameters in patients switching from lanthanum carbonate (LanC) to sucroferric oxyhydroxide (SFOH).</p><p><strong>Methods: </strong>Fifteen stable hemodialysis patients were switched from LanC to SFOH. Only nine continued on SFOH, three returned to LanC and the other three switched to sevelamer carbonate. The later six patients served as a control group to the SFOH group of nine patients. Blood was sampled on the 3-d and the last 2-d interval of the week prior to switching and six weeks after. Bicarbonate levels (HCO<sub>3</sub> <sup>-</sup>), pH, pO<sub>2</sub>, pCO<sub>2</sub> were measured, and the mean of the two measurements (3-d and 2-d interval) was calculated.</p><p><strong>Results: </strong>Comparing pre-switching to post-switching measurements in the SFOH group, no statistically significant differences were found in any of the parameters studied. The mean pre-switching HCO<sub>3</sub> <sup>-</sup> was 22.41 ± 1.66 mmol/L and the mean post-switching was 22.62 ± 2.25 mmol/L (<i>P</i> = 0.889). Respectively, the mean pH= 7.38 ± 0.03 <i>vs</i> 7.39 ± 0.03 (<i>P</i> = 0.635), mean pCO<sub>2</sub>= 38.41 ± 3.29 <i>vs</i> 38.37 ± 3.62 mmHg (<i>P</i> = 0.767), and Phosphate = 1.57 ± 0.27 <i>vs</i> 1.36 ± 0.38mmol/L (<i>P</i> = 0.214). There were not any significant differences when we performed the same analyses in the control group or between the SFOH group and control group. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.</p><p><strong>Conclusion: </strong>In our small study, switching from LanC to SFOH did not have any significant effect on blood bicarbonate levels and gas analysis, indicating that there is no need to change hemodialysis prescription regarding these parameters.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 6","pages":"123-128"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/98/WJN-7-123.PMC6181871.pdf","citationCount":"0","resultStr":"{\"title\":\"Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide.\",\"authors\":\"Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas\",\"doi\":\"10.5527/wjn.v7.i6.123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To examine possible alterations in acid-base parameters in patients switching from lanthanum carbonate (LanC) to sucroferric oxyhydroxide (SFOH).</p><p><strong>Methods: </strong>Fifteen stable hemodialysis patients were switched from LanC to SFOH. Only nine continued on SFOH, three returned to LanC and the other three switched to sevelamer carbonate. The later six patients served as a control group to the SFOH group of nine patients. Blood was sampled on the 3-d and the last 2-d interval of the week prior to switching and six weeks after. Bicarbonate levels (HCO<sub>3</sub> <sup>-</sup>), pH, pO<sub>2</sub>, pCO<sub>2</sub> were measured, and the mean of the two measurements (3-d and 2-d interval) was calculated.</p><p><strong>Results: </strong>Comparing pre-switching to post-switching measurements in the SFOH group, no statistically significant differences were found in any of the parameters studied. The mean pre-switching HCO<sub>3</sub> <sup>-</sup> was 22.41 ± 1.66 mmol/L and the mean post-switching was 22.62 ± 2.25 mmol/L (<i>P</i> = 0.889). Respectively, the mean pH= 7.38 ± 0.03 <i>vs</i> 7.39 ± 0.03 (<i>P</i> = 0.635), mean pCO<sub>2</sub>= 38.41 ± 3.29 <i>vs</i> 38.37 ± 3.62 mmHg (<i>P</i> = 0.767), and Phosphate = 1.57 ± 0.27 <i>vs</i> 1.36 ± 0.38mmol/L (<i>P</i> = 0.214). There were not any significant differences when we performed the same analyses in the control group or between the SFOH group and control group. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.</p><p><strong>Conclusion: </strong>In our small study, switching from LanC to SFOH did not have any significant effect on blood bicarbonate levels and gas analysis, indicating that there is no need to change hemodialysis prescription regarding these parameters.</p>\",\"PeriodicalId\":23745,\"journal\":{\"name\":\"World Journal of Nephrology\",\"volume\":\"7 6\",\"pages\":\"123-128\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/98/WJN-7-123.PMC6181871.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5527/wjn.v7.i6.123\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5527/wjn.v7.i6.123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:研究从碳酸镧(LanC)转向氢氧化铁(soh)的患者酸碱参数可能发生的变化。方法:将15例稳定血透患者由LanC转为SFOH。只有9个继续使用SFOH, 3个返回LanC,另外3个切换到七维拉姆碳酸。后6例患者作为SFOH组9例患者的对照组。在切换前一周和切换后六周的3-d和最后2-d间隔抽取血液。测量了碳酸氢盐(HCO3 -)、pH、pO2、pCO2水平,并计算了两者的平均值(三维和二维间隔)。结果:比较SFOH组切换前和切换后的测量结果,在研究的任何参数中均未发现统计学上的显著差异。切换前HCO3 -均值为22.41±1.66 mmol/L,切换后均值为22.62±2.25 mmol/L (P = 0.889)。平均pH= 7.38±0.03 vs 7.39±0.03 (P = 0.635),平均pCO2= 38.41±3.29 vs 38.37±3.62 mmHg (P = 0.767),平均磷酸盐= 1.57±0.27 vs 1.36±0.38mmol/L (P = 0.214)。当我们在对照组或SFOH组与对照组之间进行相同的分析时,没有任何显着差异。无论是切换前的LanC日剂量还是切换后的新粘合剂日剂量与测量参数之间都没有发现相关性。结论:在我们的小型研究中,从LanC切换到SFOH对血液碳酸氢盐水平和气体分析没有任何显著影响,表明无需改变血液透析处方的这些参数。
Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide.
Aim: To examine possible alterations in acid-base parameters in patients switching from lanthanum carbonate (LanC) to sucroferric oxyhydroxide (SFOH).
Methods: Fifteen stable hemodialysis patients were switched from LanC to SFOH. Only nine continued on SFOH, three returned to LanC and the other three switched to sevelamer carbonate. The later six patients served as a control group to the SFOH group of nine patients. Blood was sampled on the 3-d and the last 2-d interval of the week prior to switching and six weeks after. Bicarbonate levels (HCO3-), pH, pO2, pCO2 were measured, and the mean of the two measurements (3-d and 2-d interval) was calculated.
Results: Comparing pre-switching to post-switching measurements in the SFOH group, no statistically significant differences were found in any of the parameters studied. The mean pre-switching HCO3- was 22.41 ± 1.66 mmol/L and the mean post-switching was 22.62 ± 2.25 mmol/L (P = 0.889). Respectively, the mean pH= 7.38 ± 0.03 vs 7.39 ± 0.03 (P = 0.635), mean pCO2= 38.41 ± 3.29 vs 38.37 ± 3.62 mmHg (P = 0.767), and Phosphate = 1.57 ± 0.27 vs 1.36 ± 0.38mmol/L (P = 0.214). There were not any significant differences when we performed the same analyses in the control group or between the SFOH group and control group. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.
Conclusion: In our small study, switching from LanC to SFOH did not have any significant effect on blood bicarbonate levels and gas analysis, indicating that there is no need to change hemodialysis prescription regarding these parameters.